Kamada (KMDA) said Wednesday it was awarded a contract with an unnamed international organization to supply Kamrab and Varizig in Latin America for the 2025-2027 period.
Revenue under the three-year contract is expected to be about $25 million, the company said.
Kamrab is indicated for the prevention of rabies infection after contact with rabid or possibly rabid animals, while Varizig is a varicella drug for post-exposure prophylaxis in high-risk individuals, Kamada said.
The company's shares were rising past 5% in recent trading.
Price: 7.48, Change: +0.40, Percent Change: +5.64
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。